
CMV promoter
AmpR
pEE CK
5055 bp
START
Leader
SalI (1637)
VL
oriP
BsiWI (1968)
CK
STOP
polyA

Fig. 1.


CMV promoter
AmpR
pEE HC
5761 bp
START
Leader
SalI (1637)
VH
NheI (2004)
HC
oriP
polyA
STOP

Fig. 2.


IgG1

Fig. 3.


5'
3'
мРНК из лимфоцитов
Lymphocyte mRNA
5'
3'
мРНК из лимфоцитов
Lymphocyte mRNA
VK/L
VH
VK/L
CK
+
VH
VK/L
CK
VH

Фиг. 4

Fig. 4


fd ori
gIII-CT
CH1
Bst EII (948)
AmpR
pH5
4745bp
pelB
VH
Sfi I (1318)
pelB
CK
Bsi WI (1719)
VL
pBR332 ori
Nhe I (2111)
ПроPromoter

Fig. 5.


PBR322 ori
AmpR
5.5k
6k
6.5k
5k
7k
4.5k
His-tag
STOP CH1
XhoI
4k
7.5k
pLL-Fab
7757 bp
7757
NotI
Myc-tag
CH1
SeqH3b
XhoI
3.5k
500
LacI
VH
3k
Hpelb
STOP CK
Lpelb
XhoI
1k
CK
2.5k
VK
1.5k
NheI
2k
BamHI
KmR

Fig. 6.



Fig. 7


Signal (nm)
0.55
0.50
0.45
0.40
0.35
0.30
0.25
0.20
0.15
0.10
0.05
0
0
50
100
150
200
250
300
350
400
450
500
Time (s)

Fig. 8


Signal (nm)
0.45
0.40
0.35
0.30
0.25
0.20
0.15
0.10
0.05
0
0
50
100
150
200
250
300
350
400
450
500
Time (s)

Fig. 9.


Signal (nm)
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
0
50
100
150
200
250
300
350
400
450
500
Time (s)

Fig. 10


Signal (nm)
0.50
0.45
0.40
0.35
0.30
0.25
0.20
0.15
0.10
0.05
0
0
50
100
150
200
250
300
350
400
450
500
Time (s)

Fig. 11


Signal (nm)
0.25
0.20
0.15
0.10
0.05
0
0
50
100
150
200
250
300
350
400
Time (s)

Fig. 12


Signal (nm)
0.40
0.35
0.30
0.25
0.20
0.15
0.10
0.05
0
0
50
100
150
200
250
300
350
400
Time (s)

Fig. 13


Signal (nm)
0.30
0.25
0.20
0.15
0.10
0.05
0
0
50
100
150
200
250
300
350
400
Time (s)

Fig. 14


Signal (nm)
0.60
0.55
0.50
0.45
0.40
0.35
0.30
0.25
0.20
0.15
0.10
0.05
0
0
50
100
150
200
250
300
350
400
Time (s)

Fig. 15


Signal (nm)
0,6
0,4
0,2
0
0
20
40
60
80
100
120
140
160
180
200
220
Time (s)

Fig. 16


Signal (nm)
0,5
0,4
0,3
0,2
0,1
0
0
20
40
60
80
100
120
140
160
180
200
220
Time (s)

Fig. 17


Signal (nm)
0,4
0,3
0,2
0,1
0
0
20
40
60
80
100
120
140
160
180
200
220
Time (s)

Fig. 18


Signal (nm)
0,5
0,4
0,3
0,2
0,1
0
0
20
40
60
80
100
120
140
160
180
200
220
Time (s)

Fig. 19


Signal (nm)
1,2
1,0
0,8
0,6
0,4
0,2
0
0
20
40
60
80
100
120
140
160
180
200
220
Time (s)

Fig. 20


Signal (nm)
1
0.8
0.6
0.4
0.2
0
0
20
40
60
80
100
120
140
160
180
200
220
Time (s)

Fig. 21


Signal (nm)
0,6
0,4
0,2
0
0
20
40
60
80
100
120
140
160
180
200
220
Time (s)

Fig. 22


Signal (nm)
0,8
0,6
0,4
0,2
0
0
20
40
60
80
100
120
140
160
180
200
220
Time (s)

Fig. 23


polyA signal
Antibiotic R
SV40 promoter
F1origin
p-CMVe/EF1alpha
HindIII
Leader
START
INSERT
STOP
XbaI
BGH-polyA
enhancer SV40
AmpR
pSX
Rep origin1
beta-globin MAR

Fig. 24.


MEAN FLUORESCENCE INTENSITY
45000
40000
35000
30000
25000
20000
15000
10000
5000
0
0,1
1
10
100
1000
10000
100000
1000000
RITUXIMAB
BCD-132-L-077
BCD-132-L-028
CONCENTRATION OF ANTIBODIES, NG/ML

Fig. 25


25000
20000
15000
10000
5000
0
Relative fluorescence units, RFU
0,001
0,01
0,1
1
10
100
Concentration of antibodies, x3 µg/ml

Fig. 26


25000
20000
15000
10000
5000
0
Relative fluorescence units, RFU
0,001
0,01
0,1
1
10
100
CONCENTRATION OF ANTIBODIES, x3 µg/ml

Fig. 27


Relative luminescence units, RLU
900000
800000
700000
600000
500000
400000
300000
200000
100000
0
0,0001
0,001
0,01
0,1
1
10
100
1000
10000
Concentration of antibodies, x3 ng/ml

Fig. 28


900000
800000
700000
600000
500000
400000
300000
200000
100000
0
Relative luminescence units, RLU
0,0001
0,001
0,01
0,1
1
10
100
1000
10000
Concentration of antibodies, x3 ng/ml

Fig. 29


Relative luminescence units, RLU
900000
800000
700000
600000
500000
400000
300000
200000
100000
0
0,0001
0,001
0,01
0,1
1
10
100
1000
10000
Concentration of antibodies, x3 ng/ml

Fig. 30


Relative luminescence units, RLU
900000
800000
700000
600000
500000
400000
300000
200000
100000
0
0,0001
0,001
0,01
0,1
1
10
100
1000
10000
Concentration of antibodies, x3 ng/ml

Fig. 31


A
FF
Rituximab
B cell depletion, %
Concentration of antibodies, ng/ml
Б
FV
Rituximab
B cell depletion, %
Concentration of antibodies, ng/ml
B
VV
Rituximab
B cell depletion, %
Concentration of antibodies, ng/ml

Fig. 32


ADCC, %
60
50
40
30
20
10
0
10-4
10-3
10-2
10-1
100
101
102
103
Concentration of antibody, ng/ml
Rituximab
BCD-132-L-028
BCD-132-L-077

Fig. 33



Fig. 34



Fig. 35


BCD-132, 22мг/кг
BCD-132, 44мг/кг
BCD-132, 88 мг/кг
1000
800
600
400
200
0
Concentration of BCD-132-L-077, µg/ml
0
200
400
600
800
1000
Time, hours

Fig. 36